Benjamin M. Ellingson1, Jerrold L. Boxerman2, Suriya Jeyapalan3, Heinrich D. Elinzano3, Marc Goldman4, Thomas Dipetrillo5, Howard Safran6, Whitney B. Pope1
1Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; 2Diagnostic Imaging, Brown University and Rhode Island Hospital; 3Neurooncology, Brown University and Rhode Island Hospital; 4Neurosurgery, Brown University and Rhode Island Hospital; 5Radiation Oncology, Brown University and Rhode Island Hospital; 6Hematology & Oncology, Brown University and Rhode Island Hospital
Paclitaxel poliglumex (PPX) is a microtubule stabilizer and mitotic inhibitor with a radiosensitization index of 4-8, and has been proposed as a radiosensitizing agent for patients with high-grade gliomas undergoing radiation therapy with the purpose of increasing acute cytotoxicity and effectiveness of radiotherapy. The purpose of the current study was to determine whether time-dependent cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MRI data could distinguish pseudoprogression from recurrent tumor in a phase II study of PPX added to standard IMRT and TMZ therapy for newly diagnosed high-grade (WHO III-IV) gliomas.
Keywords